pLenti6/V5-p53_R249S Citations (8)
Originally described in: Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW Neoplasia. 2008 May . 10(5):450-61. PubMed
Articles Citing pLenti6/V5-p53_R249S
| Articles |
|---|
| P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance. Hashimoto A, Oikawa T, Hashimoto S, Sugino H, Yoshikawa A, Otsuka Y, Handa H, Onodera Y, Nam JM, Oneyama C, Okada M, Fukuda M, Sabe H. J Cell Biol. 2016 Apr 11;213(1):81-95. doi: 10.1083/jcb.201510002. Epub 2016 Apr 4. PubMed |
| ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance. Hashimoto A, Hashimoto S, Sugino H, Yoshikawa A, Onodera Y, Handa H, Oikawa T, Sabe H. Oncogenesis. 2016 Sep 12;5(9):e259. doi: 10.1038/oncsis.2016.60. PubMed |
| Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding. Liao P, Zeng SX, Zhou X, Chen T, Zhou F, Cao B, Jung JH, Del Sal G, Luo S, Lu H. Mol Cell. 2017 Dec 21;68(6):1134-1146.e6. doi: 10.1016/j.molcel.2017.11.006. Epub 2017 Dec 7. PubMed |
| Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. Chryplewicz A, Tienda SM, Nahotko DA, Peters PN, Lengyel E, Eckert MA. Sci Rep. 2019 Mar 26;9(1):5195. doi: 10.1038/s41598-019-41352-5. PubMed |
| Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers. Goswami MT, VanDenBerg KR, Han S, Wang LL, Singh B, Weiss T, Barlow M, Kamberov S, Wilder-Romans K, Rhodes DR, Feng FY, Tomlins SA. Mol Cancer Res. 2019 Aug;17(8):1652-1664. doi: 10.1158/1541-7786.MCR-19-0144. Epub 2019 May 20. PubMed |
| Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. Sa JK, Hwang JR, Cho YJ, Ryu JY, Choi JJ, Jeong SY, Kim J, Kim MS, Paik ES, Lee YY, Choi CH, Kim TJ, Kim BG, Bae DS, Lee Y, Her NG, Shin YJ, Cho HJ, Kim JY, Seo YJ, Koo H, Oh JW, Lee T, Kim HS, Song SY, Bae JS, Park WY, Han HD, Ahn HJ, Sood AK, Rabadan R, Lee JK, Nam DH, Lee JW. Genome Biol. 2019 Nov 26;20(1):253. doi: 10.1186/s13059-019-1848-3. PubMed |
| Efficient Modulation of TP53 Expression in Human Induced Pluripotent Stem Cells. Uhlmann C, Kuhn LM, Tigges J, Fritsche E, Kahlert UD. Curr Protoc Stem Cell Biol. 2020 Mar;52(1):e102. doi: 10.1002/cpsc.102. PubMed |
| mTOR inhibition attenuates chemosensitivity through the induction of chemotherapy resistant persisters. Liu Y, Azizian NG, Sullivan DK, Li Y. Nat Commun. 2022 Nov 17;13(1):7047. doi: 10.1038/s41467-022-34890-6. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.